Seeking Alpha

Shares of Regeneron (REGN +10.1%) roar out of the gate after the company beats the estimate of...

Shares of Regeneron (REGN +10.1%) roar out of the gate after the company beats the estimate of analysts with its Q4 report and boosts its outlook for 2012 sales on its eye drug Eylea. The news could tip off weaker sales for Roche's (RHHBY.PK) Lucentis treatment - Regeneron's main rival in the space.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs